NASDAQ: PAVSParanovus Entertainment Technology Ltd Stock
$5.10-0.10 (-1.92%)
Updated Mar 24, 2023
PAVS Price
$5.10
Fair Value Price
N/A
Market Cap
$20.17M
52 Week Low
$2.08
52 Week High
$7.40
P/E
-0.19x
P/B
0.37x
P/S
0.07x
PEG
N/A
Dividend Yield
N/A
Revenue
$95.59M
Earnings
-$58.51M
Gross Margin
0.6%
Operating Margin
-62.14%
Profit Margin
-61.2%
Debt to Equity
0.45
Operating Cash Flow
-$43M
Beta
0.35
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
PAVS Overview
Happiness Development Group Limited engages in the research, development, manufacture, and sale of nutraceutical and dietary supplement products in the People's Republic of China and internationally. The company's product category includes lucidum spore powders, cordyceps mycelia, Ejiao products, American ginseng products, other traditional Chinese herbal and animal extracts, vitamins, minerals, and amino acids. It also offers product marketing and e-commerce agency operation services under the Happy Buy platform to small and middle size businesses; and e-commerce solutions, internet information, and advertising services to the online stores or manufactures. In addition, the company provides secure transaction environment, automobile procurement, and financial services for automobile manufacturers under the Taochejun automobile sales platform. It sells its products through distributors, large-scale chain drugstores, malls, and supermarkets under the Happiness brand. The company was formerly known as Happiness Biotech Group Limited and changed its name to Happiness Development Group Limited in October 2022. Happiness Development Group Limited was founded in 2004 and is headquartered in Nanping, the People's Republic of China.
Zen Score
–
Industry Average (28)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how PAVS scored across 38 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
PAVS is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
PAVS is good value based on its book value relative to its share price (0.37x), compared to the US Drug Manufacturers - Specialty & Generic industry average (1.79x)
P/B vs Industry Valuation
PAVS is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 35 more PAVS due diligence checks available for Premium users.
Be the first to know about important PAVS news, forecast changes, insider trades & much more!
PAVS News
Valuation
PAVS fair value
Fair Value of PAVS stock based on Discounted Cash Flow (DCF)
Price
$5.10
Fair Value
$13.62
Undervalued by
62.54%
PAVS is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
PAVS price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.19x
Industry
18.14x
Market
21.37x
PAVS price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.37x
Industry
1.79x
PAVS is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
PAVS's financial health
Profit margin
Revenue
$0.0
Net Income
$0.0
Profit Margin
0%
PAVS's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
PAVS's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$76.0M
Liabilities
$24.4M
Debt to equity
0.45
PAVS's short-term assets ($45.50M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
PAVS's short-term assets ($45.50M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
PAVS's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
N/A
Investing
N/A
Financing
N/A
PAVS's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
PAVS vs Pharmaceutical Stocks
Paranovus Entertainment Technology Stock FAQ
©2023 WallStreetZen
Company
AboutBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.